Top

Published in:

01-06-2009 | IM - Review

Contemporary issues on clopidogrel therapy

Authors: Giuseppe Patti, Germano Di Sciascio

Published in: Internal and Emergency Medicine | Issue 3/2009

Abstract

In this paper, data from available studies regarding some contemporary issues on clopidogrel therapy are analyzed. In particular, the following clinical questions have been considered and addressed: (a) Is early clopidogrel treatment needed in patients with acute coronary syndromes treated medically or undergoing percutaneous coronary intervention (PCI)? (b) What is the optimal clopidogrel loading dose in patients undergoing PCI? (c) Is pre-treatment with clopidogrel before PCI needed, or can clopidogrel loading be given in the catheter laboratory before intervention, but after coronary anatomy is known? (d) What is the optimal clopidogrel strategy in patients on chronic clopidogrel therapy undergoing PCI? (e) Does the degree of clopidogrel response influence clinical outcome in patients undergoing PCI?

Schömig A, Neumann FJ, Kastrati A et al (1996) A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334:1084–1089PubMedCrossRef

Bertrand ME, Rupprecht HJ, Urban P (2000) Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102:624–629PubMed

Bhatt DL, Bertrand ME, Berger PB et al (2002) Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 39:9–14PubMedCrossRef

Yusuf S, Zhao F, Mehta SR et al (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502PubMedCrossRef

Mehta SR, Yusuf S, Peters RJ et al (2001) Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:527–533PubMedCrossRef

Sabatine MS, Cannon CP, Gibson CM et al (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. New Engl J Med 352:1179–1189PubMedCrossRef

Sabatine MS, Cannon CP, Gibson CM et al (2005) Effect of clopidogrel pre-treatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 294:1224–1232PubMedCrossRef

Chen ZM, Jiang LX, Chen YP et al (2005) Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366:1607–1621PubMedCrossRef

Ault KA, Cannon CP, Mitchell J et al (1999) Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in myocardial infarction. J Am Coll Cardiol 33:634–639PubMedCrossRef

10.

Soffer D, Moussa I, Harjai KJ et al (2003) Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? Catheter Cardiovasc Interv 59:21–25PubMedCrossRef

11.

Yusuf S, Mehta SR, Zhao F et al (2003) Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 107:966–972PubMedCrossRef

12.

Verheugt FW, Montalescot G, Sabatine MS et al (2007) Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial. J Thromb Thrombolysis 23:173–179PubMedCrossRef

13.

Steinhubl SR, Berger PB, Mann JTIII et al (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288:2411–2420PubMedCrossRef

14.

Steinhubl SR, Darrah S, Brennan D et al (2003) Optimal duration of pre-treatment with clopidogrel prior to PCI: data from the CREDO trial. Circulation 108(Suppl I):I1742

15.

Sabatine MS, Hamdalla HN, Mehta SR et al (2008) Efficacy and safety of clopidogrel pre-treatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. Am Heart J 155:910–917PubMedCrossRef

16.

Chan AW, Moliterno DJ, Berger PB et al (2003) Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival. J Am Coll Cardiol 42:1188–1195PubMedCrossRef

17.

Szük T, Gyöngyösi M, Homorodi N et al (2007) Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pre-treatment 6 to 24 hours before stenting in a large unselected patient cohort. Am Heart J 153:289–295PubMedCrossRef

18.

Moore RK, Lowe R, Grayson AD et al (2007) A study comparing the incidence and predictors of creatine kinase MB and troponin T release after coronary angioplasty. Does clopidogrel preloading reduce myocardial necrosis following elective percutaneous coronary intervention? Int J Cardiol 116:93–97PubMedCrossRef

19.

Nienhuis MB, Ottervanger JP, Miedema K et al (2006) Pre-treatment with clopidogrel and postprocedure troponin elevation after elective percutaneous coronary intervention. Thromb Haemost 95:337–340PubMed

20.

Cadroy Y, Bossavy JP, Thalamas C et al (2000) Early potent antithrombotic effect with combined aspirin and LD of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 101:2823–2828PubMed

21.

Gorog P, Ridler CD, Rees GM et al (1995) Evidence against hypercoagulability in coronary artery disease. Thromb Res 79:377–385PubMedCrossRef

22.

Muller I, Seyfarth M, Rudiger S et al (2001) Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 85:92–93PubMedCrossRef

23.

Leimbach ME, Peyrou V, Marzec UM et al (1999) Single-dose clopidogrel inhibition of platelet adenosine receptor function in patients with atherosclerotic coronary artery disease. Circulation 100(Suppl I):I681

24.

Kandzari DE, Berger PB, Kastrati A et al (2004) Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 44:2133–2136PubMedCrossRef

25.

Kastrati A, Mehilli J, Schuhlen H et al (2004) A clinical trial of abciximab in elective percutaneous coronary intervention after pre-treatment with clopidogrel. N Engl J Med 350:232–238PubMedCrossRef

26.

Patti G, Colonna G, Pasceri V et al (2005) A randomized trial of high loading dose of clopidogrel for reduction of peri-procedural myocardial infarction in patients undergoing coronary intervention results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 111:2099–2106PubMedCrossRef

27.

Patti G, Pasceri V, Di Sciascio G (2005) Optimal antiplatelet therapy in patients undergoing percutaneous coronary intervention: new insights from the randomized ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Vasc Dis Manag 2:60–62

28.

Cuisset T, Frere C, Quilici J et al (2006) Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 48:1339–1345PubMedCrossRef

29.

Silber S, Albertsson P, Avilés FF et al (2005) Guidelines for percutaneous coronary interventions. The task force for percutaneous coronary interventions of the European society of cardiology. Eur Heart J 26:804–847PubMedCrossRef

30.

King SBIII, Smith SC, Hirshfeld JW et al (2008) 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. J Am Coll Cardiol 51:172–209PubMedCrossRef

31.

Kastrati A, Mehilli J, Neumann FJ et al (2006) Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pre-treatment: the ISAR-REACT 2 randomized trial. JAMA 295:1531–1538PubMedCrossRef

32.

Montalescot G, Sideris G, Meuleman C et al (2006) A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 48:931–938PubMedCrossRef

33.

Von Beckerath N, Taubert D, Pogatsa-Murray G et al (2005) Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation 112:2946–2950

34.

L’Allier PL, Ducrocq G, Pranno N et al (2008) Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study. J Am Coll Cardiol 51:1066–1072PubMedCrossRef

35.

Bonello L, Camoin-Jau L, Arques S et al (2008) Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance. J Am Coll Cardiol 51:1404–1411PubMedCrossRef

36.

Angiolillo DJ, Shoemaker SB, Desai B et al (2007) Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115:708–716PubMedCrossRef

37.

von Beckerath N, Kastrati A, Wieczorek A et al (2007) A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 28:1814–1819CrossRef

38.

Smith SC Jr, Feldman TE, Hirshfeld JW Jr et al (2006) ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 47:e1–e121PubMedCrossRef

39.

Mehta SR, Granger CB, Eikelboom JW et al (2007) Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 50:1742–1751PubMedCrossRef

40.

Rao SV, O’Grady K, Pieper KS et al (2005) Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 96:1200–1206PubMedCrossRef

41.

Fox KAA, Mehta SR, Peters R et al (2004) Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial. Circulation 110:1202–1208PubMedCrossRef

42.

Widimsky P, Motovská Z, Simek S et al (2008) Clopidogrel pre-treatment in stable angina: for all patients >6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. Eur Heart J 29:1495–1503PubMedCrossRef

43.

Patti G, Colonna G, Pasceri V et al (2007) Is 600 mg in-lab clopidogrel loading equivalent to “upstream” pre-treatment in patients undergoing percutaneous coronary intervention? Results of the ARMYDA-5 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. Late breaking clinical trials, TCT sessions, October 2007. Available at http://www.cardiosource.com/img/armyda501.ppt

44.

Anderson JL, Adams CD, Antman EM et al (2007) American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine. J Am Coll Cardiol 50:e1–e157PubMedCrossRef

45.

Sharis PJ, Cannon CP, Loscalzo J (1998) The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 129:394–405PubMed

46.

Kastrati A, von Beckerath N, Joost A et al (2004) Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 110:1916–1919PubMedCrossRef

47.

Di Sciascio G, Patti G, Colonna G et al (2008) Clopidogrel reloading before percutaneous coronary intervention improves outcome in patients with acute coronary syndromes receiving chronic clopidogrel therapy. Results of the ARMYDA-RELOAD (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-RELOAD) randomized trial. Late breaking clinical trials, SCAI-ACCi2 sessions, March 2008. Available at http://www.cardiosource.com/rapidnewssummaries/summary.asp?SumID=242

48.

Collet JP, Silvain J, Landivier A et al (2008) Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study. Circulation 118:1225–1233PubMedCrossRef

49.

Gurbel PA, Bliden KP, Hiatt BL et al (2003) Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pre-treatment platelet reactivity. Circulation 107:2908–2913PubMedCrossRef

50.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2004) High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 25:1903–1910PubMedCrossRef

51.

Lau WC, Waskell LA, Watkins PB et al (2003) Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug–drug interaction. Circulation 107:32–37PubMedCrossRef

52.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2006) Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 26:1895–1900PubMedCrossRef

53.

Frere C, Cuisset T, Morange PE et al (2008) Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 101:1088–1093PubMedCrossRef

54.

Giusti B, Gori AM, Marcucci R et al (2007) Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 17:1057–1064PubMedCrossRef

55.

Fontana P, Dupont A, Gandrille S et al (2003) Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 108:989–995PubMedCrossRef

56.

Serebruany VL (2007) The “Clopidogrel Resistance” trap. Am J Cardiol 100:1044–1046PubMedCrossRef

57.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2005) Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54:2430–2435PubMedCrossRef

58.

Gurbel PA, Bliden KP, Guyer K et al (2005) Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study. J Am Coll Cardiol 46:1820–1826PubMedCrossRef

59.

Serebruany VL, Steinhubl SR, Berger PB et al (2005) Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45:246–251PubMedCrossRef

60.

Gurbel PA, Bliden KP, Zaman KA et al (2005) Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 111:1153–1159PubMedCrossRef

61.

Lev EI, Patel RT, Maresh KJ et al (2006) Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 47:27–33PubMedCrossRef

62.

Cuisset T, Frere C, Quilici J et al (2007) High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb Haemost 97:282–287PubMed

63.

Buch AN, Singh S, Roy P et al (2007) Measuring aspirin resistance, clopidogrel responsiveness, and post-procedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. Am J Cardiol 99:1518–1522PubMedCrossRef

64.

Cuisset T, Hamilos M, Sarma J et al (2008) Relation of low response to clopidogrel assessed with point-of-care assay to peri-procedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. Am J Cardiol 101:1700–1703PubMedCrossRef

65.

Cuisset T, Frere C, Quilici J et al (2006) High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 4:542–549PubMedCrossRef

66.

Geisler T, Langer H, Wydymus M et al (2006) Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 27:2420–2425PubMedCrossRef

67.

Hochholzer W, Trenk D, Bestehorn HP et al (2006) Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48:1742–1750PubMedCrossRef

68.

Patti G, Nusca A, Mangiacapra F et al (2008) Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention. Results of the ARMYDA-PRO (Antiplatelet Therapy for Reduction of MYocardial Damage During Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 52:1128–1133PubMedCrossRef

69.

Matetzky S, Shenkman B, Guetta V et al (2003) Clopidogrel resistance in patients with acute coronary syndrome is associated with increased risk of recurrent cardiovascular events. Circulation 108:501CrossRef

70.

Bliden KP, DiChiara J, Tantry US et al (2007) Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention. J Am Coll Cardiol 49:657–666PubMedCrossRef

71.

Price MJ, Endemann S, Gollapudi RR et al (2008) Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29:992–1000PubMedCrossRef

72.

Gurbel PA, Bliden KP, Samara W et al (2005) Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST study. J Am Coll Cardiol 46:1827–1832PubMedCrossRef

73.

Mueller I, Besta F, Schulz C et al (2003) Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 89:783–787

74.

Klamroth R, Hoffmann S, Andresen D et al (2004) Clopidogrel resistance and aspirin resistance—a cause of coronary artery stent thrombosis? Blood 104:104B

75.

Ajzenberg N, Aubry P, Huisse MG et al (2005) Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis. J Am Coll Cardiol 45:1753–1756PubMedCrossRef

76.

Wenaweser P, Dorffler-Melly J, Imboden K et al (2005) Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 45:1748–1752PubMedCrossRef

77.

Lev EI, Alviar CL, Arikan ME et al (2007) Platelet reactivity in patients with subacute stent thrombosis compared with non-stent-related acute myocardial infarction. Am Heart J 153:41.e1–41.e6CrossRef

78.

Buonamici P, Marcucci R, Migliorini A et al (2007) Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 49:2312–2317PubMedCrossRef

Title: Contemporary issues on clopidogrel therapy
Authors: Giuseppe Patti
Germano Di Sciascio
Publication date: 01-06-2009
Publisher: Springer Milan
Published in: Internal and Emergency Medicine / Issue 3/2009
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-008-0220-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

Hypothermia: an under-estimated risk

Management of intradialytic hypertension: old problem, old drug?

Keep an eye on the pupil: developing countries under chemical attack

The ugly duckling and the swan

Usefulness of procalcitonin for diagnosis of infective endocarditis

Cardiopulmonary exercise testing in heart failure: from ugly duckling to swan

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials